BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29251392)

  • 1. Impact of 2013 ASCO/CAP HER2 reporting guidelines in breast cancer: An assessment study from Indian oncology centre that primarily performs HER2 IHC testing with special emphasis on IHC equivocal category.
    Pasricha S; Gupta G; Garg R; Sharma A; Gandhi JS; Durga G; Kamboj M; Grover S; Mehta A
    Breast J; 2018 Jul; 24(4):468-472. PubMed ID: 29251392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE; Marotti JD; Memoli VA; Wells WA; Tafe LJ
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
    Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
    Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
    Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
    Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
    Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
    Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization.
    Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B
    Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
    Varga Z; Noske A
    PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
    Ragazzi M; Bisagni A; Gasparini E; Kuhn E; Bassano C; Tamagnini I; Foroni M; Bortesi M; Falco G; Ferrari G; Braglia L; Savoldi L; Bologna A; Di Cicilia R; Bisagni G; Gardini G
    Breast; 2017 Aug; 34():65-72. PubMed ID: 28521178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
    Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
    Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines.
    Xu FP; Wang K; Xu J; Chen J; Zhang YF; Wu HM; Zhang MH; Long XX; Luo XL; Zhang KP; Lin DY; Liu YH
    Breast Cancer Res Treat; 2017 Dec; 166(3):757-764. PubMed ID: 28861637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of 2013 Updated ASCO/CAP HER2 Guidelines on the Diagnosis and Management of Invasive Breast Cancer: A Single-Center Study of 1739 Cases.
    Zhang X; Bleiweiss I; Jaffer S; Nayak A
    Clin Breast Cancer; 2017 Oct; 17(6):486-492. PubMed ID: 28433541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
    Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
    Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines.
    Shah MV; Wiktor AE; Meyer RG; Tenner KS; Ballman KV; Green SJ; Sukov WR; Ketterling RP; Perez EA; Jenkins RB
    J Clin Oncol; 2016 Oct; 34(29):3502-3510. PubMed ID: 27458302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
    Curado M; Caramelo AS; Eloy C; Polónia A
    Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
    Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
    PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 Equivocal (Score = 2+) Breast Carcinoma Cases Identified by Immunohistochemistry at a South African Hospital. What is the Impact of Fluorescent In Situ Hybridization Testing?
    Mohanlal RD; Bouwer N; Willem P
    Appl Immunohistochem Mol Morphol; 2023 Sep; 31(8):555-560. PubMed ID: 37471623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.